Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board.
Burkard ME, Deming DA, Parsons BM, Kenny PA, Schuh MR, Leal T, Uboha N, Lang JM, Thompson MA, Warren R, Bauman J, Mably MS, Laffin J, Paschal CR, Lager AM, Lee K, Matkowskyj KA, Buehler DG, Rehrauer WM, Kolesar J. Burkard ME, et al. Among authors: warren r. JCO Precis Oncol. 2017 Jul 5;1:PO.16.00022. doi: 10.1200/PO.16.00022. eCollection 2017. JCO Precis Oncol. 2017. PMID: 32913980 Free PMC article.
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Chang JE, McQuinn D, Hyun M, Kim K, Kenkre VP, Rajguru SA, Pophali PA, Endres M, Howard M, Wassenaar T, Warren RC, Mattison RJ, Wisinski KB, Fletcher CD. Chang JE, et al. Clin Lymphoma Myeloma Leuk. 2024 Oct 9:S2152-2650(24)02358-9. doi: 10.1016/j.clml.2024.09.014. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39477701
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
Armstrong AW, Lebwohl M, Warren RB, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp KA, Kisa RM, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo MJ, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Armstrong AW, et al. Among authors: warren rb. JAMA Dermatol. 2024 Nov 27. doi: 10.1001/jamadermatol.2024.4688. Online ahead of print. JAMA Dermatol. 2024. PMID: 39602111
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.
Merola JF, Gottlieb AB, Pinter A, Elewski B, Gooderham M, Warren RB, Piaserico S, Wixted K, Cross N, Tilt N, Wiegratz S, Mrowietz U. Merola JF, et al. Among authors: warren rb. Dermatol Ther (Heidelb). 2024 Dec;14(12):3291-3306. doi: 10.1007/s13555-024-01295-w. Epub 2024 Nov 22. Dermatol Ther (Heidelb). 2024. PMID: 39578348 Free PMC article.
Bad company? The pericardium microbiome in people investigated for tuberculous pericarditis in an HIV-prevalent setting.
Nyawo G, Naidoo CC, Wu BG, Kwok B, Clemente JC, Li Y, Minnies S, Reeve B, Moodley S, John TJ, Karamchand S, Singh S, Pecararo A, Doubell A, Kyriakakis C, Warren R, Segal LN, Theron G. Nyawo G, et al. Among authors: warren r. Microbes Infect. 2024 Nov 9:105434. doi: 10.1016/j.micinf.2024.105434. Online ahead of print. Microbes Infect. 2024. PMID: 39528106 Free article.
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.
Warren RB, Pavlovsky L, Costanzo A, Bukhalo M, Korman NJ, Huang YH, Kokolakis G, Pinter A, Ibrahim N, Zheng Y, Drogaris L, Stakias V, Soliman AM, Rubant S, Thaçi D. Warren RB, et al. Dermatol Ther (Heidelb). 2024 Dec;14(12):3273-3290. doi: 10.1007/s13555-024-01292-z. Epub 2024 Nov 8. Dermatol Ther (Heidelb). 2024. PMID: 39516454 Free PMC article.
3,468 results